Key facts
- • FDA-approved Type 2 diabetes only (May 2022) — weight loss is off-label.
- • Same molecule as Zepbound (tirzepatide), same doses — different FDA indication.
- • Cash list ~$1,069/mo — similar to Zepbound pen pricing.
- • SURPASS trials: 8-12% weight loss alongside HbA1c improvement in T2D patients.
- • For pure weight loss → request Zepbound (insurance covers on-label indication).
FDA indications
Mounjaro FDA-approved indications:
- Glycemic control in adults with Type 2 diabetes mellitus (May 2022)
- SURPASS-CVOT (cardiovascular outcomes trial) ongoing — may expand indication to CV risk reduction in T2D + CVD
Weight loss prescribing is off-label. Prescribers increasingly direct pure weight-loss patients to Zepbound vs Mounjaro to avoid insurance denial loop.
Cost landscape
| Path | Cost |
|---|---|
| Cash list (no insurance) | ~$1,069/mo |
| Commercial insurance T2D copay | $25-100/mo typical |
| Lilly patient assistance (T2D, qualified) | $0-100/mo |
| Medicare Part D with IRA cap | $0-100/mo |
| Compounded tirzepatide | $199-399/mo |
| Off-label weight loss (cash) | Full ~$1,069/mo list |
Mounjaro vs Zepbound
Same medication, different FDA-approved indication. Key practical differences:
- Insurance: T2D patients get Mounjaro covered. Weight-loss-only patients get Zepbound covered.
- Supply: Periodically constrained (one or the other may be in shortage). Switching between is straightforward (same molecule).
- Cost: Cash list parity. With insurance, depends on indication.
- Vial pricing: Zepbound has LillyDirect ~$299/mo vial option; Mounjaro does not (only autoinjector pen).
Mounjaro vs Ozempic for T2D
| Factor | Mounjaro | Ozempic |
|---|---|---|
| Receptor mechanism | Dual GIP/GLP-1 | GLP-1 only |
| HbA1c reduction | ~2.0-2.4% | ~1.5-1.8% |
| Weight loss alongside | 8-12% | 6-9% |
| Max dose | 15 mg | 2.0 mg |
| Cash list | ~$1,069/mo | ~$968/mo |
| Cardiovascular indication | Pending SURPASS-CVOT | Established (SUSTAIN-6) |
Dose schedule
- Weeks 1-4: 2.5 mg weekly — initiation
- Weeks 5-8: 5 mg weekly
- Weeks 9-12: 7.5 mg weekly
- Weeks 13-16: 10 mg weekly
- Weeks 17-20: 12.5 mg weekly
- Weeks 21+: 15 mg weekly — max dose (same as Zepbound)
FAQ
Mounjaro vs Zepbound — same drug?
Same molecule (tirzepatide), different FDA indications. Mounjaro: FDA-approved Type 2 diabetes only (2022). Zepbound: FDA-approved chronic weight management (Nov 2023). Same manufacturer (Eli Lilly), same dose strengths (2.5-15 mg weekly). Mounjaro off-label for weight loss similar to Ozempic vs Wegovy parallel.
Is Mounjaro FDA-approved for weight loss?
No. Mounjaro is FDA-approved only for glycemic control in Type 2 diabetes. Off-label weight loss prescribing is legal but rarely insurance-covered. Patients seeking pure weight loss should request Zepbound (FDA-approved indication) or Wegovy.
How much weight do you lose on Mounjaro?
SURPASS trials (T2D population, on-label use): 8-12% weight loss alongside HbA1c reduction. Off-label use in obesity (similar to Zepbound): ~15-20% expected at higher doses. Lower than dedicated Zepbound trials (22.5% SURMOUNT-1) because T2D patients have different metabolic baseline.
What does Mounjaro cost?
Cash list ~$1,069/mo (similar to Zepbound pen). With commercial insurance T2D copay: $25-100/mo. With Medicare Part D + IRA $2,100 cap: $0-100/mo. Off-label weight loss use rarely insurance-covered = full $1,069 cash.
Mounjaro vs Ozempic for T2D?
Mounjaro more effective (dual GIP+GLP-1 vs Ozempic's GLP-1 only) with greater HbA1c reduction + weight loss. Mounjaro slightly newer (2022 vs 2017 Ozempic). Cash list comparable. Insurance coverage similar for T2D indication. If insurance covers both, Mounjaro usually preferred clinically.
Compounded tirzepatide vs Mounjaro?
Same molecule but different supply. Compounded tirzepatide pharmacy-mixed under 503A, not FDA-approved as finished product. FDA ended tirzepatide compounding shortage March 2025; ongoing enforcement against telehealth firms continuing to prescribe. Cheaper ($199-399/mo) but carries FDA risk.
Best telehealth for Mounjaro?
For T2D indication: PlushCare, LifeMD, Ro Body (strong insurance handling). For off-label weight loss self-pay: direct manufacturer through Eli Lilly patient assistance. Compounded path (Eden/Henry) cheaper if accept FDA enforcement risk.
Bottom line
Mounjaro is the T2D version of tirzepatide. If T2D, request Mounjaro (insurance covers + best-in-class glycemic control). If weight loss only, request Zepbound (same drug, on-label, insurance covers). Compare providers.
Sources
Editorial only — not medical advice. Pricing accurate as of 2026-06-05.